166 related articles for article (PubMed ID: 37029759)
21. Molecular mechanism study of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
Wu X; Guo Q; Li Q; Wan S; Li Z; Zhang J
J Biomol Struct Dyn; 2022 Aug; 40(13):5848-5857. PubMed ID: 33459177
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation.
Yuan Z; Zhang M; Chang L; Chen X; Ruan S; Shi S; Zhang Y; Zhu L; Li H; Li S
J Mol Model; 2024 Apr; 30(5):131. PubMed ID: 38613643
[TBL] [Abstract][Full Text] [Related]
23. DFT, molecular docking and molecular dynamics simulation studies on some recent natural products revealing their EGFR tyrosine kinase inhibition potential.
Erdogan T; Oguz Erdogan F
J Biomol Struct Dyn; 2024 Apr; 42(6):2942-2956. PubMed ID: 37144731
[TBL] [Abstract][Full Text] [Related]
24. Computational insights into allosteric inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach.
Kumar V; Singh P; Parate S; Singh R; Ro HS; Song KS; Lee KW; Park YM
J Mol Graph Model; 2024 Jul; 130():108789. PubMed ID: 38718434
[TBL] [Abstract][Full Text] [Related]
25. In silico target specific design of potential quinazoline-based anti-NSCLC agents.
Mohammadnejadi E; Razzaghi-Asl N
J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424
[TBL] [Abstract][Full Text] [Related]
26. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel IDO1/TDO2 dual inhibitors: a consensus Virtual screening approach with molecular dynamics simulations, and binding free energy analysis.
Hanif N; Sari S
J Biomol Struct Dyn; 2024 Mar; ():1-17. PubMed ID: 38498355
[TBL] [Abstract][Full Text] [Related]
28. Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation.
Singh A; Mishra A
J Biomol Struct Dyn; 2023 Jul; 41(10):4534-4548. PubMed ID: 35510318
[TBL] [Abstract][Full Text] [Related]
29. Drug repurposing combined with MM/PBSA based validation strategies towards MEK inhibitors screening.
Thirunavukkarasu MK; Karuppasamy R
J Biomol Struct Dyn; 2022; 40(22):12392-12403. PubMed ID: 34459701
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophore based virtual screening, molecular docking and molecular dynamic simulation studies for finding ROS1 kinase inhibitors as potential drug molecules.
Vanajothi R; Vedagiri H; Al-Ansari MM; Al-Humaid LA; Kumpati P
J Biomol Struct Dyn; 2022 May; 40(8):3385-3399. PubMed ID: 33200682
[TBL] [Abstract][Full Text] [Related]
31. Structure-based virtual screening, molecular dynamics simulation and MM-PBSA toward identifying the inhibitors for two-component regulatory system protein NarL of
Kumar N; Srivastava R; Prakash A; Lynn AM
J Biomol Struct Dyn; 2020 Jul; 38(11):3396-3410. PubMed ID: 31422761
[TBL] [Abstract][Full Text] [Related]
32. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Rathi E; Kumar A; Kini SG
J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
[TBL] [Abstract][Full Text] [Related]
33. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
[TBL] [Abstract][Full Text] [Related]
34. A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
Biochemistry; 2019 Oct; 58(41):4246-4259. PubMed ID: 31589411
[TBL] [Abstract][Full Text] [Related]
35. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
36. Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches.
Ala C; Joshi RP; Gupta P; Ramalingam S; Sankaranarayanan M
J Biomol Struct Dyn; 2024; 42(1):261-273. PubMed ID: 37061929
[TBL] [Abstract][Full Text] [Related]
37. Molecular dynamic simulations based discovery and development of thiazolidin-4-one derivatives as EGFR inhibitors targeting resistance in non-small cell lung cancer (NSCLC).
Karnik KS; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Wakte PS
J Biomol Struct Dyn; 2023 Jul; 41(10):4696-4710. PubMed ID: 35532095
[TBL] [Abstract][Full Text] [Related]
38. Discovering potential inhibitors of Raf proto-oncogene serine/threonine kinase 1: a virtual screening approach towards anticancer drug development.
Khan A; Bealy MA; Alharbi B; Khan S; Alharethi SH; Al-Soud WA; Mohammad T; Hassan MI; Alshammari N; Ahmed Al-Keridis L
J Biomol Struct Dyn; 2024; 42(4):1846-1857. PubMed ID: 37104027
[TBL] [Abstract][Full Text] [Related]
39. High-throughput virtual screening approach of natural compounds as target inhibitors of plasmepsin-II.
En-Nahli F; Baammi S; Hajji H; Alaqarbeh M; Lakhlifi T; Bouachrine M
J Biomol Struct Dyn; 2023 Nov; 41(19):10070-10080. PubMed ID: 36469727
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations.
Ahmadi A; Mohammadnejadi E; Razzaghi-Asl N
Comput Biol Med; 2023 Sep; 163():107204. PubMed ID: 37421739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
